Cargando…

A case report of therapeutically challenging chronic actinic dermatitis

Chronic actinic dermatitis is a difficult to treat photodermatitis. Treatment is not standardized and involves topical corticosteroids and immunomodulators, and systemic immunosuppressive agents. We present a case with partial response to dupilumab, a monoclonal antibody approved for atopic dermatit...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Luvneet, Pratt, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501497/
https://www.ncbi.nlm.nih.gov/pubmed/31105944
http://dx.doi.org/10.1177/2050313X19845235
_version_ 1783416129253801984
author Verma, Luvneet
Pratt, Melanie
author_facet Verma, Luvneet
Pratt, Melanie
author_sort Verma, Luvneet
collection PubMed
description Chronic actinic dermatitis is a difficult to treat photodermatitis. Treatment is not standardized and involves topical corticosteroids and immunomodulators, and systemic immunosuppressive agents. We present a case with partial response to dupilumab, a monoclonal antibody approved for atopic dermatitis. In recalcitrant cases, systemic agents such as methotrexate, azathioprine, mycophenolate mofetil, and thalidomide, extracorpeal electrophoresis, and low-dose psoralen and ultraviolet A can also be considered.
format Online
Article
Text
id pubmed-6501497
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65014972019-05-17 A case report of therapeutically challenging chronic actinic dermatitis Verma, Luvneet Pratt, Melanie SAGE Open Med Case Rep JCMS Case Report Chronic actinic dermatitis is a difficult to treat photodermatitis. Treatment is not standardized and involves topical corticosteroids and immunomodulators, and systemic immunosuppressive agents. We present a case with partial response to dupilumab, a monoclonal antibody approved for atopic dermatitis. In recalcitrant cases, systemic agents such as methotrexate, azathioprine, mycophenolate mofetil, and thalidomide, extracorpeal electrophoresis, and low-dose psoralen and ultraviolet A can also be considered. SAGE Publications 2019-05-02 /pmc/articles/PMC6501497/ /pubmed/31105944 http://dx.doi.org/10.1177/2050313X19845235 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle JCMS Case Report
Verma, Luvneet
Pratt, Melanie
A case report of therapeutically challenging chronic actinic dermatitis
title A case report of therapeutically challenging chronic actinic dermatitis
title_full A case report of therapeutically challenging chronic actinic dermatitis
title_fullStr A case report of therapeutically challenging chronic actinic dermatitis
title_full_unstemmed A case report of therapeutically challenging chronic actinic dermatitis
title_short A case report of therapeutically challenging chronic actinic dermatitis
title_sort case report of therapeutically challenging chronic actinic dermatitis
topic JCMS Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6501497/
https://www.ncbi.nlm.nih.gov/pubmed/31105944
http://dx.doi.org/10.1177/2050313X19845235
work_keys_str_mv AT vermaluvneet acasereportoftherapeuticallychallengingchronicactinicdermatitis
AT prattmelanie acasereportoftherapeuticallychallengingchronicactinicdermatitis
AT vermaluvneet casereportoftherapeuticallychallengingchronicactinicdermatitis
AT prattmelanie casereportoftherapeuticallychallengingchronicactinicdermatitis